Business
Abeona is a commercial-stage biopharmaceutical company developing cell and gene therapies for life-threatening diseases, led by ZEVASKYN for recessive dystrophic epidermolysis bullosa wounds.
Abeona won ZEVASKYN approval and reported net income, but cash burn and insider selling remain the issue.
The read at a glance✓ Audited against SEC data
- Business mix — Commercial-stage cell and gene therapy companyNote
- Revenue — Revenue +66.3% to $5.82MOK
- Profitability — Net income swung to $71.2MOK
- Cash quality — Free cash flow fell to -$84.3MWatch
- Balance sheet — Equity +261.6% to $159MOK
- Insiders — 0 buys / 23 sellsWatch
- Accounting — Altman-Z distress; product-revenue audit focusWatch
Where the revenue comes from
Fiscal 2025, as ABEONA THERAPEUTICS INC. reports it. History and quarterly detail are in the app.
- License$3.4M
- Product$2.4M
Leadership changes
From ABEONA THERAPEUTICS INC.'s own filings, the day they're filed.
- Michael Amoroso · member · departureeff. 2026-06-11
- Bernhardt G. Zeiher · directors · appointmenteff. 2024-08-08
- Keith A. Goldan · director · appointment
Latest filings
- 10-Q · Quarterly report2026-08-13
- 8-K · Company announcement2026-08-13
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-06-12
- 8-K · Company announcement2026-06-10
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ABEONA THERAPEUTICS INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.